NeuroVive Pharmaceutical AB Proposes Resolution On Private Placement And Rights Issue Totaling Approximately SEK 111 M

Published: Nov 20, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

On 20 November 2013, the Board of Directors of NeuroVive Pharmaceutical AB (STO:NVP) (publ), (the “Company”) decided to convene an Extraordinary General Meeting (EGM) and to propose that the Meeting approves a private placement to institutional investors (the “Private Placement”) and a rights issue for existing shareholders (the “Rights Issue”), collectively termed (the “New Share Issues”). Upon full subscription of the New Share Issues, the Company will raise approximately SEK 111 m before issue expenses. There is an additional over-allotment option of up to approx. SEK 10 m for use in potential over-subscription.The issue proceeds will be used for NeuroVive’s continued operations in drug development, clinical trials and activities to prepare the market.

Help employers find you! Check out all the jobs and post your resume.

Back to news